BackRegulus Therapeutics Overview

Regulus Therapeutics Accounts Payable

Track Regulus Therapeutics's accounts payable ($200K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$200000.00
↓ 50.74% YoYΔ $-206000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Regulus Therapeutics Accounts Payable History

Loading

Regulus Therapeutics vs. peers: Accounts Payable Comparison

Loading

Regulus Therapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Regulus Therapeutics (RGLS) FAQ

As of the most recent data (March 2025), RGLS shows a accounts payable of $200K. That compares with $410K in the prior-year period — down 50.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RGLS's accounts payable is now $200K (was $410K) — a 50.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Regulus Therapeutics is outperforming or lagging.

Tracking RGLS's accounts payable over time shows whether Regulus Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $200K That compares with $410K in the prior-year period — down 50.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Regulus Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $200K) with ownership activity and broader fundamentals.

Regulus Therapeutics's accounts payable is $200K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.